GGrantIndex
Sort

51,593 grants matching hepatitis

Retrovial Infections of the Nervous System in Peru

$555,061
Joseph Raymond Zunt · University Of Washington · R01 · FY2009 · NS

Dietary treatment of Glucose Transporter Type 1 Deficiency (G1D)

$554,982
Juan M. Pascual · Ut Southwestern Medical Center · R01 · FY2020 · NS

Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH

$554,963
Kenneth Cusi · University Of Florida · R01 · FY2022 · DK

Cytapheresis Of Volunteer Donors (MRI 2003-054)

$554,949
Josephine Egan · National Institute On Aging · ZID · FY2011 · AG

WOMEN DRUG USERS, THEIR MALE PARTNERS AND HIV RISK

$554,924
National Development &Res Institutes · R01 · FY2003 · DA

Roles of SLC26 Transporters in Urinary Oxalate Excretion and Kidney Disease

$554,868
Peter S Aronson · Yale University · R01 · FY2021 · DK

Roles of SLC26 Transporters in Urinary Oxalate Excretion and Kidney Disease

$554,868
Peter S Aronson · Yale University · R01 · FY2018 · DK

Roles of SLC26 Transporters in Urinary Oxalate Excretion and Kidney Disease

$554,867
Peter S Aronson · Yale University · R01 · FY2022 · DK

Roles of SLC26 Transporters in Urinary Oxalate Excretion and Kidney Disease

$554,867
Peter S Aronson · Yale University · R01 · FY2020 · DK

Roles of SLC26 Transporters in Urinary Oxalate Excretion and Kidney Disease

$554,867
Peter S Aronson · Yale University · R01 · FY2019 · DK

HCC Risk Stratification in MAFLD Cirrhosis

$554,835
Hashem B El-Serag · Baylor College Of Medicine · P01 · FY2025 · CA

The application of human collagen kinetic biomarkers to anti-fibrotic drug develo

$554,823
Scott M Turner · Kinemed, Inc. · R44 · FY2009 · CA

Mechanisms of Innate and Adaptive Immune Responses to AAV-FVIII Gene Transfer

$554,819
Roland W. Herzog · Indiana University Indianapolis · P01 · FY2022 · HL

Multi-Center Study of the Treatment of T2DM in Youth

$554,784
Sonia Caprio · Yale University · U01 · FY2007 · DK

Understanding B cell memory in response to diverse virus infections

$554,702
Michel C Nussenzweig · Rockefeller University · U19 · FY2021 · AI

Understanding B cell memory in response to diverse virus infections

$554,701
Michel C Nussenzweig · Rockefeller University · U19 · FY2020 · AI

Accessible Care Intervention for Engaging People who Inject Illicit Drugs (PWID) in Hepatitis C Care

$554,667
Pedro Mateu-Gelabert · Graduate School Of Public Health And Health Policy · R01 · FY2019 · DA

Engineering viral-specific T cells with improved function and persistence

$554,648
E. John Wherry · University Of Pennsylvania · P01 · FY2025 · AI

Novel mechanism based treatment to improve tissue injury in alcoholic hepatitis

$554,644
Srinivasan Dasarathy · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · AA

Understanding the underlying toxicological mechanisms of drug-hormone interactions to improve the safety profile of antiviral medications in pregnant people, developing fetuses, and neonates

$554,627
Jed Noah Lampe · University Of Colorado Denver · R01 · FY2025 · AI

MAF1 Function and Metabolic Inefficiency

$554,600
Ian M Willis · Albert Einstein College Of Medicine, Inc · R01 · FY2017 · GM

Atherogenic Patheways Mediated by FOXO

$554,526
Domenico Accili · Columbia University Health Sciences · P01 · FY2007 · HL

Mechanistic function of HCV NS5A targeted by the potent inhibitors

$554,525
Minkyung Yi · University Of Texas Med Br Galveston · R01 · FY2022 · AI

Mechanistic function of HCV NS5A targeted by the potent inhibitors

$554,525
Minkyung Yi · University Of Texas Med Br Galveston · R01 · FY2021 · AI

Mechanistic function of HCV NS5A targeted by the potent inhibitors

$554,525
Minkyung Yi · University Of Texas Med Br Galveston · R01 · FY2024 · AI